BFM
KLRS

Boothbay Fund Management’s Kalaris Therapeutics KLRS Stock Holding History

Boothbay Fund Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10
Closed -$557K – 2169
2021
Q1 		$557K Buy
+10
New +$8.4K 0.02% 887

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's KLRS Position: Q2 2026 in Review

Boothbay Fund Management held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 92,261 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

Boothbay Fund Management first reported a position in KLRS in Q4 2025 and has held it in 3 quarters since. The position peaked at $779K in Q4 2025. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Boothbay Fund Management held 92,261 shares of Kalaris Therapeutics worth $376K as of Q2 2026.
  • Boothbay Fund Management left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1656 holding.
  • Boothbay Fund Management first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's Kalaris Therapeutics position peaked at $779K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.